Case Type: Mergers & Acquisitions

Rover Group, Inc. (Nasdaq: ROVR), relating to its sale to affiliates of Blackstone Inc. Under the terms of the agreement, ROVR shareholders will receive $11.00 in cash pers share they own.

ImmunoGen, Inc. (Nasdaq: IMGN), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN), relating to its proposed sale to Sycona Ltd. Under the terms of the agreement, FRLN shareholders will receive $6.50 in cash per share they own.

P&F Industries, Inc. (Nasdaq: PFIN), relating to its proposed sale to ShoreView Industries. Under the terms of the agreement, PFIN shareholders are expected to receive $13.00 in cash per share they own.

Homology Medicines, Inc. (Nasdaq: FIXX), relating to its proposed merger with Q32 Bio, Inc. Under the terms of the agreement, FIXX shareholders are expected to own approximately 25% of the combined company.

GAN Limited (Nasdaq: GAN), relating to its proposed sale to Sega Sammy Creation Inc. Under the terms of the agreement, GAN shareholders will receive $1.97 in cash per share they own.

Northern Genesis Acquisition Corp. II (NYSE: NGAB), relating to its 2021 merger with Embark Technology, Inc.

BigBear.ai Holdings, Inc. (NYSE: BBAI), relating to its proposed merger with Pangiam Intermediate Holdings, LLC.

Patriot Transportation Holding, Inc. (Nasdaq: PATI), relating to its proposed sale to United Petroleum Transports, Inc. Under the terms of the agreement, PATI shareholders will receive $16.26 in cash per share they own.

Eargo, Inc. (Nasdaq: EAR), relating to its proposed sale to an affiliate of Patient Square Capital. Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.